H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM

Cancer Research

Volumn 70, Issue 20, 2010, Pages 7830-7840

  Chen, Min Wei ^a   Hua, Kuo Tai ^a   Kao, Hsin Jung ^a   Chi, Chia Chun ^a   Wei, Lin Hung ^b   Johansson, Gunnar ^a   Shiah, Shine Gwo ^d   Chen, Pai Sheng ^a   Jeng, Yung Ming ^b   Cheng, Tsu Yao ^b   Lai, Tsung Ching ^c   Chang, Jeng Shou ^c   Jan, Yi Hua ^c   Chien, Ming Hsien ^f   Yang, Chih Jen ^e   Huang, Ming Shyan ^e   Hsiao, Michael ^c   Kuo, Min Liang ^a,g  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; EPITHELIAL CELL ADHESION MOLECULE; HETEROCHROMATIN PROTEIN 1; HISTONE DEACETYLASE 1; HISTONE METHYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RNA INTERFERENCE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE SILENCING; GENES, REPORTER; HISTOCOMPATIBILITY ANTIGENS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LUCIFERASES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, NEOPLASM;

EID: 78049307486     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0833     Document Type: Article

References (44)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
2. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20:3139-55.
3. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006;2:e40.
4. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
5. Ballestar E, Paz MF, Valle L, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22:6335-45. (Pubitemid 37522590)
6. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;62:7213-8. (Pubitemid 36025241)
7. Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 2001;29:4598-606.
8. Dong KB, Maksakova IA, Mohn F, et al. DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity. EMBO J 2008;27:2691-701.
9. Ikegami K, Iwatani M, Suzuki M, et al. Genome-wide and locus-specific DNA hypomethylation in G9a deficient mouse embryonic stem cells. Genes Cells 2007;12:1-11. (Pubitemid 44971094)
10. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95. (Pubitemid 37443893)
11. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW. 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 2007;26:77-90. (Pubitemid 46067333)
12. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6. (Pubitemid 40943093)
13. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008;15:1968-76.
14. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008;47:701-6.
15. Tachibana M, Sugimoto K, Fukushima T, Shinkai Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem 2001;276:25309-17.
16. Rice JC, Briggs SD, Ueberheide B, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 2003;12:1591-8. (Pubitemid 38037025)
17. Tachibana M, Sugimoto K, Nozaki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 2002;16:1779-91. (Pubitemid 34803894)
18. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647:21-9.
19. Kirmizis A, Bartley SM, Farnham PJ. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2003;2:113-21.
20. Kondo Y, Shen L, Suzuki S, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007;37:974-83. (Pubitemid 47399927)
21. Watanabe H, Soejima K, Yasuda H, et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 2008;8:15.
22. Kondo Y, Shen L, Ahmed S, et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS ONE 2008;3:e2037. (Pubitemid 352024760)
23. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3:55-63.
24. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007;67:547-56.
25. Choi JH, Song YS, Yoon JS, Song KW, Lee YY. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS 2010;118:196-202.
26. Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nat Med 2010;16:286-94.
27. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
28. Chu YW, Yang PC, Yang SC, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997;17:353-60.
29. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 2003;9:5532-9. (Pubitemid 37499472)
30. Tai KY, Shiah SG, Shieh YS, et al. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 2007;26:3989-97.
31. Dobrovic A, Bianco T, Tan LW, Sanders T, Hussey D. Screening for and analysis of methylation differences using methylation-sensitive single-strand conformation analysis. Methods 2002;27:134-8. (Pubitemid 34757124)
32. Tachibana M, Ueda J, Fukuda M, et al. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-9. Genes Dev 2005;19:815-26.
33. Zhang X, Tamaru H, Khan SI, et al. Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase. Cell 2002;111:117-27.
34. Zhang X, Yang Z, Khan SI, et al. Structural basis for the product specificity of histone lysine methyltransferases. Mol Cell 2003;12:177-85. (Pubitemid 36957834)
35. McLaughlin PM, Trzpis M, Kroesen BJ, et al. Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines. Cancer Gene Ther 2004;11:603-12. (Pubitemid 39195410)
36. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174:1619-28.
37. Ellinger J, Kahl P, von der Gathen J, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010;70:61-9.
38. Ng SS, Kavanagh KL, McDonough MA, et al. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature 2007;448:87-91.
39. Cloos PA, Christensen J, Agger K, et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006;442:307-11. (Pubitemid 44114906)
40. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119:941-53. (Pubitemid 40037608)
41. Tachibana M, Matsumura Y, Fukuda M, Kimura H, Shinkai Y. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J 2008;27:2681-90.
42. Ueda J, Tachibana M, Ikura T, Shinkai Y. Zinc finger protein Wiz links G9a/GLP histone methyltransferases to the co-repressor molecule CtBP. J Biol Chem 2006;281:20120-8. (Pubitemid 44065786)
43. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46.
44. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH, Nagtegaal ID. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 2007;20:221-32.